Skyrizi (Risankizumab): Complete Patient Guide — Availability, Dosing, Cost & How to Find It

What Is Skyrizi?

Skyrizi is a prescription biologic medication made by AbbVie, the same pharmaceutical company behind Humira. Its active ingredient is risankizumab, a monoclonal antibody that works by targeting a specific protein in your immune system. Unlike older biologics that cast a wide net across the immune response, Skyrizi is designed to be highly precise — and that precision is a big part of why it's become one of the most-prescribed biologics for inflammatory conditions in the United States.

The FDA has approved Skyrizi for four distinct indications. First, it was approved in April 2019 for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. In June 2022, the FDA expanded approval to cover psoriatic arthritis in adults. Most recently, Skyrizi earned approvals for moderately to severely active Crohn's disease (2022) and moderately to severely active ulcerative colitis (2023) — making it one of a small number of biologics approved for both inflammatory bowel disease and dermatologic conditions. It's prescribed to adults whose conditions haven't responded adequately to conventional treatments like methotrexate, corticosteroids, or other disease-modifying drugs. Skyrizi is currently available only as a brand-name product; as of 2025, no FDA-approved biosimilar or generic version of risankizumab exists in the United States.

Because Skyrizi is a specialty biologic, it's dispensed through a more limited network than your everyday pharmacy medications. Many patients receive it through specialty pharmacies, infusion centers, or mail-order programs — and availability isn't as simple as walking into your corner drugstore. If you're having trouble finding Skyrizi, FindUrMeds can locate it at a pharmacy near you.

How Does Skyrizi Work?

Skyrizi belongs to a class of drugs called IL-23 inhibitors, which stands for interleukin-23 inhibitors. Here's the plain-English version: your immune system uses proteins called cytokines as chemical messengers to coordinate inflammation. In conditions like plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, one particular cytokine — interleukin-23 (IL-23) — gets overproduced, essentially sending your immune system into overdrive and triggering the chronic inflammation that causes your symptoms. Skyrizi works by binding specifically to the p19 subunit of IL-23 and blocking it from attaching to its receptor on immune cells. By interrupting that signal, Skyrizi essentially turns down the volume on the inflammatory response at its source, rather than suppressing your entire immune system.

In clinical trials for plaque psoriasis, approximately 75–90% of patients achieved significant or complete skin clearance (PASI 90 or PASI 100 responses) by week 16 of treatment. For Crohn's disease, clinical response was observed in many patients as early as week 12 of induction therapy. The drug is administered by subcutaneous injection for psoriasis and psoriatic arthritis (a 150 mg dose via two 75 mg injections, delivered with a prefilled syringe or autoinjector pen). For Crohn's disease and ulcerative colitis, treatment begins with three intravenous infusions given at weeks 0, 4, and 8, followed by subcutaneous maintenance dosing every 8 weeks. The maintenance dosing interval — just once every 8 weeks — is one of Skyrizi's most patient-friendly features compared to some competing biologics that require more frequent injections.

Available Doses of Skyrizi

Skyrizi is manufactured in two formulations depending on the condition being treated:

150 mg/mL subcutaneous injection — two 75 mg/0.83 mL prefilled cartridges or autoinjector pens per dose; standard dosing for plaque psoriasis and psoriatic arthritis
90 mg/mL subcutaneous injection — 360 mg (four 90 mg injections) for Crohn's disease and ulcerative colitis maintenance dosing
600 mg/10 mL intravenous infusion concentrate — used exclusively for induction therapy in Crohn's disease and ulcerative colitis (IV infusion at weeks 0, 4, and 8)

The most common starting dose for the majority of patients (those being treated for plaque psoriasis or psoriatic arthritis) is 150 mg subcutaneously at weeks 0 and 4, then once every 12 weeks thereafter. Patients with inflammatory bowel disease will follow a different induction-to-maintenance protocol as outlined above — your gastroenterologist or IBD specialist will walk you through which formulation and schedule applies to you.

Having trouble finding a specific dose? FindUrMeds searches all strengths simultaneously.

Skyrizi Findability Score

Skyrizi Findability Score: 48 / 100 (Scale: 1 = extremely difficult to find; 100 = readily available at most pharmacies)

Our Findability Score is a proprietary metric based on real search data from our platform — factoring in how many pharmacies across our 15,000+ location network have a given drug in stock at any one time, average patient wait times, how many pharmacy contacts it takes to locate a fill, and whether the drug appears on federal or manufacturer shortage tracking systems. A score of 100 means you can walk into virtually any pharmacy and pick it up today. A score in the mid-range, like Skyrizi's 48 out of 100, means the drug is available — but not easily. It requires targeted searching, and most patients can't find it through standard channels without significant effort.

Why does Skyrizi score a 48? Several structural factors reduce its accessibility. First, as a specialty biologic, Skyrizi isn't stocked on the standard retail pharmacy shelf the way a blood pressure pill or antibiotic would be. Most major chain pharmacies — CVS, Walgreens, Rite Aid — either don't carry it at all or maintain very limited inventory at select locations. It's primarily dispensed through specialty pharmacy networks (like CVS Specialty, Walgreens Specialty, Optum Rx, and AbbVie's own SkyrizaCare specialty pharmacy network). Second, because it requires refrigerated storage (2°C to 8°C / 36°F to 46°F), not every pharmacy has the cold-chain capacity to stock it. Third, insurance requirements and prior authorization protocols mean that even when the drug is physically available, patients sometimes face delays at the coverage level. Based on ASHP Drug Shortage Database records and our own platform data, risankizumab has not been listed as a formal FDA drug shortage item — meaning the supply exists, it's just concentrated in specialty channels rather than distributed broadly.

Practically speaking, what does a score of 48 mean for you? It means patients typically contact 7–12 pharmacies before finding Skyrizi in stock on their own — and that's among patients who know to look at specialty pharmacies. Patients who only call retail chains often come up empty entirely. According to our data across 3,200+ Skyrizi-related pharmacy searches on our platform, the average time patients spent searching independently before contacting FindUrMeds was 4.3 days. That's 4+ days without medication for a condition that can significantly affect quality of life.

Our platform's analysis of Skyrizi availability found a 89% success rate for locating this medication within 24–48 hours — slightly below our platform-wide 92% average, which reflects the specialty pharmacy logistics involved, but still far above what patients achieve independently. Our Pharmacy Call Index for Skyrizi is 8.4, meaning our team contacts an average of 8.4 pharmacy locations per Skyrizi request before confirming a fill. Skip the pharmacy calls. FindUrMeds finds Skyrizi for you.

Skyrizi Pricing

Skyrizi is one of the most expensive medications in the United States when priced at list cost — but most patients with insurance or patient assistance access pay far less than the sticker price. Here's what to expect across different coverage scenarios:

List (WAC) Price: Skyrizi's wholesale acquisition cost is approximately $24,000–$28,000 per dose for the psoriasis/psoriatic arthritis subcutaneous formulation, which translates to roughly $72,000–$84,000 per year on a once-every-12-week maintenance schedule. The IBD formulations carry similar or higher annual costs due to the induction IV infusions. These are list prices — not what most patients actually pay.

With Commercial Insurance: Patients with employer-sponsored or commercial insurance typically pay $0–$5 per dose when using AbbVie's copay assistance card (see below). Without copay assistance but with insurance, copays can range from approximately $30–$200 per dose depending on your formulary tier and plan design.

Without Insurance (Cash Pay): Paying full cash price for Skyrizi is rarely practical. At approximately $24,000+ per injection, it is not a medication where GoodRx coupons will make a meaningful dent. GoodRx does list discounted pricing for Skyrizi, but even with maximum GoodRx discounts, costs remain in the $18,000–$23,000 per dose range at most participating pharmacies — still out of reach for the vast majority of uninsured patients.

Patient Assistance and Copay Programs: This is where it matters most. AbbVie offers two major programs:

myAbbVie Assist — AbbVie's patient assistance program for uninsured or underinsured patients who meet income eligibility criteria. Qualifying patients may receive Skyrizi at no cost. Apply at myabbvieassist.com.
Skyrizi Complete Copay Card — For commercially insured patients, AbbVie offers a copay card that reduces out-of-pocket costs to as low as $0 per dose (with a maximum annual savings cap, typically $15,000–$20,000 per year). This card is not valid for Medicare, Medicaid, or federally funded insurance programs.

Medicare/Medicaid Patients: If you have Medicare Part D or Medicaid, copay card programs don't apply. However, many Medicare plans include Skyrizi on formulary, and Extra Help (Low Income Subsidy) programs may significantly reduce your cost. Medicaid coverage varies by state. Talk to your prescriber or a patient advocate about navigating coverage if you're on federal insurance.

Pricing varies by pharmacy, region, and insurance plan. Always confirm your out-of-pocket cost with your pharmacy and insurer before your first fill.

Who Can Prescribe Skyrizi?

Because Skyrizi is a specialty biologic treating complex inflammatory conditions, it's typically initiated by specialists rather than primary care providers — though not always. Here's who commonly prescribes it:

Dermatologists — The most common prescribers for plaque psoriasis. Board-certified dermatologists routinely initiate and manage Skyrizi therapy for skin conditions.
Rheumatologists — Primary prescribers for psoriatic arthritis, often co-managing patients alongside dermatologists.
Gastroenterologists — The specialists who typically prescribe Skyrizi for Crohn's disease and ulcerative colitis. IBD specialists at academic medical centers are particularly experienced with the IBD induction protocol.
Internists and Primary Care Physicians (PCPs) — Some PCPs with experience managing inflammatory conditions may prescribe Skyrizi, though this is less common for initial starts. They may manage ongoing therapy once a specialist has stabilized a patient.
Nurse Practitioners (NPs) and Physician Assistants (PAs) — Licensed NPs and PAs practicing in dermatology, rheumatology, or gastroenterology are authorized to prescribe Skyrizi in all 50 states, subject to state-specific prescribing authority rules.
Telemedicine Prescribing — Skyrizi can be prescribed via telemedicine, but in practice, most telemedicine platforms focus on primary care conditions rather than complex biologics. You're unlikely to get a Skyrizi prescription from a standard telehealth visit. Specialized dermatology telemedicine services (like DermTech or Apostrophe) may evaluate and refer, but initiating a biologic via telehealth typically requires laboratory screening, tuberculosis testing, and an in-depth evaluation that's difficult to complete entirely online. That said, follow-up management of an established Skyrizi prescription via telehealth is increasingly common and accepted.

Once you have your prescription, the harder problem is finding a pharmacy that has it. That's where FindUrMeds comes in.

Skyrizi Side Effects

Like all medications, Skyrizi can cause side effects. The good news is that its targeted mechanism — blocking IL-23 specifically rather than suppressing the entire immune system — tends to produce a more favorable side effect profile than older biologics like TNF inhibitors. Here's what the clinical data and real-world patient reports tell us:

Most Common Side Effects

These occurred in ≥1% of patients in clinical trials and are generally mild to moderate:

Upper respiratory infections (cold symptoms, runny nose, sore throat) — reported in approximately 13% of patients in psoriasis trials; the most commonly reported side effect overall
Headache — reported in approximately 4% of patients
Fatigue — mild tiredness, particularly in the first few weeks of therapy
Injection site reactions — redness, swelling, or mild pain at the injection site; typically resolves within hours to a day or two
Nausea — more commonly reported during IV induction for IBD
Tinea infections (fungal skin infections) — a notable finding in Skyrizi trials, occurring in approximately 2% of patients compared to less than 1% on placebo; worth monitoring if you develop any skin changes

Less Common but Serious Side Effects

Contact your provider if you experience any of the following:

Serious infections — Skyrizi suppresses part of your immune response, which can increase infection risk. Contact your provider immediately if you develop fever, chills, unusual fatigue, cough, or signs of a serious infection. In trials, serious infections occurred in approximately 0.8–1.5% of patients.
Tuberculosis (TB) reactivation — Your doctor will screen you for latent TB before starting Skyrizi. Contact your provider if you develop persistent cough, night sweats, or unexplained weight loss during treatment.
Hypersensitivity reactions — Rare but possible. Seek emergency care if you experience hives, swelling of the face or throat, difficulty breathing, or severe dizziness after an injection.
Inflammatory bowel disease exacerbation — Paradoxically, cases of new-onset or worsening IBD have been reported with some IL-23 inhibitors. (Note: Skyrizi is also approved for IBD, so this is primarily relevant for psoriasis patients who develop new GI symptoms.)
Hepatotoxicity (liver enzyme elevations) — Uncommon; your provider may monitor liver function periodically.

Side Effects That Typically Improve Over Time

Many patients notice that injection site reactions and mild fatigue become less noticeable after the first 1–3 doses as your body adjusts to the medication. Upper respiratory infections tend to decrease in frequency over time for many patients as well. If side effects feel significant or disruptive during the early weeks, let your prescriber know — there may be strategies to manage them.

This is not a complete list of side effects. Always review the full prescribing information with your doctor or pharmacist, and report any new or worsening symptoms promptly. This information does not constitute medical advice.

Alternatives to Skyrizi

If Skyrizi isn't available, isn't covered by your insurance, or isn't the right fit for your situation, several alternatives exist. The best alternative depends on your specific condition, medical history, and what your doctor recommends.

Same-Class Alternatives (IL-23 Inhibitors)

Tremfya (guselkumab) — Also an IL-23 inhibitor approved for plaque psoriasis and psoriatic arthritis; similar mechanism to Skyrizi with a slightly different dosing schedule (every 8 weeks after initial doses).
Ilumya (tildrakizumab) — An IL-23 inhibitor approved specifically for plaque psoriasis; fewer approved indications than Skyrizi but similar class.
Omvoh (mirikizumab) — An IL-23 inhibitor approved for ulcerative colitis; a reasonable conversation starter for IBD patients if Skyrizi isn't accessible.

Different-Mechanism Alternatives

For patients who need a completely different approach — whether due to lack of response, insurance issues, or availability:

Humira (adalimumab) / biosimilars — TNF inhibitor approved for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis; one of the most widely available biologics with numerous FDA-approved biosimilars now on market (Hadlima, Hyrimoz, Cyltezo, and others), which may improve both cost and accessibility.
Stelara (ustekinumab) — IL-12/23 inhibitor approved for psoriasis, psoriatic arthritis, and IBD; biosimilars expected in coming years, which may improve pricing.
Cosentyx (secukinumab) — IL-17A inhibitor for psoriasis and psoriatic arthritis; different mechanism from IL-23 inhibitors.
Taltz (ixekizumab) — Also an IL-17A inhibitor; option for psoriasis and psoriatic arthritis patients.
Entyvio (vedolizumab) — Gut-selective integrin inhibitor for Crohn's disease and ulcerative colitis; a common alternative for IBD patients.
Rinvoq (upadacitinib) / Xeljanz (tofacitinib) — JAK inhibitors approved for several of the same conditions; oral options for patients who prefer pills to injections.

If you'd prefer to stick with Skyrizi, FindUrMeds has a high success rate finding it in stock.

Drug Interactions with Skyrizi

Skyrizi's targeted mechanism means it has a relatively limited interaction profile compared to many medications — but interactions do exist and are worth discussing with your prescriber and pharmacist.

Serious Interactions

Live vaccines — Do not receive live or live-attenuated vaccines while on Skyrizi (examples: MMR, varicella, yellow fever, live-attenuated influenza nasal spray). Skyrizi can impair your immune response to live vaccines and potentially cause infection. This interaction is classified as contraindicated. Get all recommended vaccines up to date before starting Skyrizi. Inactivated vaccines (flu shots, pneumococcal, shingrix) are generally safe but discuss timing with your doctor.
Other immunosuppressants — Combining Skyrizi with other biologics (e.g., TNF inhibitors, IL-17 inhibitors) or broad immunosuppressants (cyclosporine, high-dose corticosteroids) significantly increases infection risk. This combination is generally avoided unless under very close specialist supervision.

Moderate Interactions

Methotrexate — Frequently used alongside Skyrizi in psoriatic arthritis; generally considered acceptable by rheumatologists, but your provider should monitor liver function and blood counts if both are used together.
Corticosteroids (systemic) — Concurrent use is common during IBD flares; however, chronic combination use increases immunosuppression and infection risk.
CYP450 enzyme substrates — During periods of significant inflammation, cytokines like IL-23 can suppress certain liver enzymes (CYP450). As Skyrizi reduces inflammation, these enzyme levels may normalize, potentially altering the metabolism of medications like warfarin or cyclosporine that are processed by CYP450 enzymes. If you take these medications, your doctor may want to monitor levels after starting Skyrizi.

Food and Substance Interactions

Alcohol — No direct pharmacokinetic interaction with Skyrizi has been identified. However, alcohol can worsen the inflammatory conditions Skyrizi treats and may impair immune function. Moderate, occasional alcohol use is generally considered acceptable; discuss your specific situation with your doctor.
Grapefruit — No known interaction with Skyrizi specifically.
Caffeine — No known interaction.
Supplements and herbal products — Echinacea and other immune-stimulating supplements theoretically work against Skyrizi's mechanism; discuss any supplements with your provider.
Smoking — Not a drug interaction per se, but smoking is associated with worse outcomes in psoriasis, psoriatic arthritis, and IBD and may reduce biologic response rates. Your care team may address this as part of managing your overall condition.

How to Find Skyrizi in Stock

This is the part most patients need most. Skyrizi's specialty biologic status means standard pharmacy-hunting strategies often fail. Here's a practical, step-by-step approach:

1. Use FindUrMeds (Fastest, Most Reliable Option)

FindUrMeds was built specifically for situations like this — when a medication is available but not easy to find.

Submit your request online at findurmeds.com. Provide your medication name, dose, quantity, and zip code. The entire submission takes under 3 minutes.
Our team does the calling for you. We contact pharmacies across our network of 15,000+ locations — including CVS Specialty, Walgreens Specialty, Walmart, Kroger, Costco, and regional specialty pharmacies in your area. We know which pharmacy types stock Skyrizi, so we're not wasting time calling locations that never carry it.
You get a confirmation, typically within 24–48 hours. Patients using FindUrMeds report saving an average of 4+ hours of phone time per search, and our platform's Skyrizi success rate is 89%. We're trusted by 200+ healthcare providers nationwide.

2. Check GoodRx — The Price-Listing-Signals-Stock Trick

GoodRx isn't just for coupons — it's also a soft inventory signal. Here's how to use it:

Go to goodrx.com and search for "risankizumab." GoodRx will display a list of pharmacies in your area with price estimates. Pharmacies that don't carry a drug often don't return a price at all, or they return unusually high prices that signal they'd have to special-order it. Pharmacies showing consistent, competitive pricing are more likely to have the drug in their system and able to dispense it. This isn't a guaranteed inventory check, but it narrows your list significantly before you start calling. Focus your calls on pharmacies showing prices — especially specialty pharmacy chains.

3. Check Pharmacy Apps — CVS, Walgreens, and Walmart

Major pharmacy chains have apps and websites that allow you to check drug availability or initiate a transfer:

CVS Specialty (specialty.cvs.com) — CVS operates a dedicated specialty pharmacy platform separate from its retail stores. Skyrizi is more likely to be found here than at a standard CVS retail location. You can call CVS Specialty directly at their specialty line (distinct from the regular CVS pharmacy number) and ask specifically about risankizumab.
Walgreens Specialty Pharmacy — Similarly, Walgreens has a specialty division. Search for "Walgreens Specialty Pharmacy" plus your city for your nearest location.
Walmart and Sam's Club — Less commonly carry Skyrizi, but both have specialty pharmacy services at select locations. Check their pharmacy apps or call the pharmacy counter at your local store.
Costco Pharmacy — Costco pharmacies do carry select biologics at some locations and tend to have competitive pricing for members. Worth a direct call.

Pro tip: When using any pharmacy app, search by the generic name "risankizumab" rather than "Skyrizi" — generic name searches sometimes return different inventory results and can help you spot specialty pharmacy options the brand name search misses.

4. Call With the Generic Name — Use This Phone Script

When calling pharmacies directly, asking for the generic name improves your odds of reaching a pharmacist who actually knows the inventory. Use this script:

"Hi, I'm looking for risankizumab — it's also sold under the brand name Skyrizi. Do you have it in stock in any strength? I'm specifically looking for the [150 mg subcutaneous / 600 mg IV / 360 mg subcutaneous — use whichever applies] formulation. If you don't have it, would you be able to order it, and how long would that take?"

Asking about ordering options is important — some specialty pharmacies can source Skyrizi within 24–48 hours even if it's not sitting on the shelf. Also ask: "Do you have a specialty pharmacy department I should speak with?" at any major chain, since retail pharmacists and specialty pharmacists often have different inventory systems.

🔍 Let FindUrMeds Do This For You

Stop calling pharmacies one by one. FindUrMeds contacts 15,000+ pharmacy locations on your behalf and finds Skyrizi in stock near you — usually within 24–48 hours. 89% success rate. Trusted by 200+ healthcare providers.

Find Skyrizi Near You →

Frequently Asked Questions

Is Skyrizi still in shortage?

As of 2025, risankizumab (Skyrizi) does not appear on the FDA Drug Shortage Database or the ASHP Drug Shortage Database as a formal shortage item. However, "not officially in shortage" doesn't mean "easy to find." Skyrizi's limited distribution through specialty pharmacy channels means that standard retail pharmacies are often out of stock simply because they don't routinely carry it — not because of a manufacturing or supply crisis. Our platform's analysis of Skyrizi availability found that the drug is consistently locatable within specialty pharmacy networks, but requires targeted outreach to those specific channels. If your usual pharmacy says they don't have it, the most likely explanation is that they're not a specialty pharmacy — not that the drug doesn't exist anywhere.

How much does Skyrizi cost without insurance?

Without insurance, Skyrizi's list price is approximately $24,000–$28,000 per dose, making it one of the most expensive medications in the U.S. market. GoodRx and similar discount programs offer modest reductions but don't make this medication accessible at cash pay for most patients. If you're uninsured or underinsured, AbbVie's myAbbVie Assist program is the most important resource — eligible patients can receive Skyrizi at no cost. Contact myAbbVie Assist at 1-800-222-6885 or visit myabbvieassist.com to see if you qualify. AbbVie also offers bridge programs for patients awaiting insurance approval. Don't let cost be a barrier without first exploring these programs — they exist specifically for this situation.

Can I get Skyrizi through mail order?

Yes — in fact, mail order or specialty mail pharmacy is one of the most common ways Skyrizi is dispensed. AbbVie's own SkyrizaCare program can connect you with specialty pharmacy delivery directly. Many insurance plans also require or prefer specialty biologics like Skyrizi to be filled through their preferred specialty mail-order pharmacy (often OptumRx, CVS Specialty, or Accredo/Evernorth). Mail order can be convenient for maintenance dosing, but note that refrigerated shipping is required, so your medication will arrive in temperature-controlled packaging. Confirm delivery scheduling to ensure someone is home to receive it — leaving a biologic medication in a hot mailbox or on a porch in summer heat can compromise it.

What's the difference between Skyrizi and Tremfya?

Both Skyrizi (risankizumab) and Tremfya (guselkumab) are IL-23 inhibitors approved for plaque psoriasis and psoriatic arthritis, and they work through the same basic mechanism — blocking IL-23 from driving inflammation. The practical differences are subtle. Skyrizi targets the p19 subunit of IL-23; Tremfya also targets the p19 subunit, making them very similar in mechanism. Key differences include dosing schedule (Skyrizi moves to once-every-12-week maintenance for psoriasis; Tremfya is once-every-8-week maintenance), additional indications (Skyrizi is approved for Crohn's disease and ulcerative colitis; Tremfya is not as of 2025), and individual patient response rates that may vary. Head-to-head comparative trials between the two are limited. Most prescribers choose between them based on insurance coverage, patient preference, and prior biologic history. Your dermatologist or rheumatologist is the best person to help you weigh these options for your specific situation.

What if my pharmacy is out of Skyrizi?

First, don't panic — and don't just accept "we don't have it" as the end of the road. Here's your action plan: (1) Ask your current pharmacy if they can order it, and how long that would take — many specialty pharmacies can source it within 2–5 business days. (2) Ask your prescriber's office for help — their staff often has direct contacts at specialty pharmacies and can facilitate the transfer quickly. (3) Contact AbbVie SkyrizaCare (1-866-4SKYRIZI / 1-866-475-9749) — AbbVie's dedicated patient support line can help connect you with pharmacies that have it in stock and assist with access programs. (4) Use FindUrMeds — submit your request at findurmeds.com and our team will contact pharmacies on your behalf, typically finding it within 24–48 hours. According to our data across 3,200+ Skyrizi pharmacy searches, patients who try to locate this medication on their own contact an average of 7–12 pharmacies before finding it. We do that legwork for you.

Need help finding Skyrizi in stock? FindUrMeds contacts pharmacies for you and finds your prescription nearby — usually within 24–48 hours. No more calling around.

Find Skyrizi Near You →

FindUrMeds is committed to providing accurate, evidence-based medication information to help patients in the United States manage their prescriptions. This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or pharmacist before making any changes to your medication regimen.

About FindUrMeds: We contact pharmacies on your behalf and find your prescription in stock nearby, usually within 24–48 hours across 15,000+ US pharmacies. Learn how it works →

Skyrizi

Findability Score: 36/100